针对2型糖尿病的伊梅格林:其有效性及其对和肝功能潜在益处的洞察力
Asuka Uto1, Yuki Ishinoda1, Takamasa Asaga1
1Department of Endocrinology and Metabolism, National Defense Medical College, Tokorozawa, JPN.
Cureus
|September 6, 2024
概括
伊梅格林在6个月内显著改善了2型糖尿病患者的HbA1c. 这种新的口服抗高血糖药在早期观察中也显示出对和肝功能的潜在益处.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 伊梅格林是一种新的口服抗高血糖药物,在日本批准用于治疗2型糖尿病 (T2DM).
- 关于其实际有效性和安全性的现实数据有限.
- 这项研究解决了对伊梅格林林有效性的临床数据的需求.
研究的目的:
- 为了回顾评估imeglimin在T2DM患者的临床疗效.
- 为了评估六个月的血糖控制 (HbA1c) 和其他生物标志物的变化.
- 为了研究对和肝功能的潜在影响.
主要方法:
- 十名T2DM患者的单中心回顾性分析.
- 主要终点:从基线到六个月的HbA1c变化.
- 二次分析包括人口,脏,肝脏和脂质参数,以及短暂的弹性体.
主要成果:
- 六个月后HbA1c从8.1%降至6.9% (P=0.01) 的显著降低.
- 没有观察到对功能的不良影响;白蛋白水平显示下降趋势.
- 非酒精性脂肪性肝病 (NAFLD) 病例表现出改善肝脂肪含量的趋势.
结论:
- 伊梅格林在T2DM中显示出对血糖控制的有希望的疗效.
- 药物可能为脏和肝脏健康提供额外的好处.
- 需要进一步的长期研究来证实这些发现.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K


